Literature DB >> 27476883

Tweaking Mesenchymal Stem/Progenitor Cell Immunomodulatory Properties with Viral Vectors Delivering Cytokines.

Paola Quaranta1, Daniele Focosi2, Giulia Freer1,3, Mauro Pistello1,3.   

Abstract

Mesenchymal Stem Cells (MSCs) can be found in various body sites. Their main role is to differentiate into cartilage, bone, muscle, and fat cells to allow tissue maintenance and repair. During inflammation, MSCs exhibit important immunomodulatory properties that are not constitutive, but require activation, upon which they may exert immunosuppressive functions. MSCs are defined as "sensors of inflammation" since they modulate their ability of interfering with the immune system both in vitro and in vivo upon interaction with different factors. MSCs may influence immune responses through different mechanisms, such as direct cell-to-cell contact, release of soluble factors, and through the induction of anergy and apoptosis. Human MSCs are defined as plastic-adherent cells expressing specific surface molecules. Lack of MHC class II antigens makes them appealing as allogeneic tools for the therapy of both autoimmune diseases and cancer. MSC therapeutic potential could be highly enhanced by the expression of exogenous cytokines provided by transduction with viral vectors. In this review, we attempt to summarize the results of a great number of in vitro and in vivo studies aimed at improving the ability of MSCs as immunomodulators in the therapy of autoimmune, degenerative diseases and cancer. We will also compare results obtained with different vectors to deliver heterologous genes to these cells.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27476883     DOI: 10.1089/scd.2016.0145

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  6 in total

Review 1.  Basic and Preclinical Research for Personalized Medicine.

Authors:  Wanda Lattanzi; Cristian Ripoli; Viviana Greco; Marta Barba; Federica Iavarone; Angelo Minucci; Andrea Urbani; Claudio Grassi; Ornella Parolini
Journal:  J Pers Med       Date:  2021-04-29

2.  Mesenchymal Stromal Cell-Based Therapy: New Perspectives and Challenges.

Authors:  Mehdi Najar; Fatima Bouhtit; Rahma Melki; Hassan Afif; Abdellah Hamal; Hassan Fahmi; Makram Merimi; Laurence Lagneaux
Journal:  J Clin Med       Date:  2019-05-08       Impact factor: 4.241

3.  Impaired immunomodulatory capacity in adipose tissue-derived mesenchymal stem/stromal cells isolated from obese patients.

Authors:  Xiang-Yang Zhu; Nattawat Klomjit; Sabena M Conley; Megan M Ostlie; Kyra L Jordan; Amir Lerman; Lilach O Lerman
Journal:  J Cell Mol Med       Date:  2021-08-21       Impact factor: 5.310

Review 4.  Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer.

Authors:  Chie Kudo-Saito; Narikazu Boku; Hidekazu Hirano; Hirokazu Shoji
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

Review 5.  Genetically engineered mesenchymal stem cells: targeted delivery of immunomodulatory agents for tumor eradication.

Authors:  Meysam Mosallaei; Miganoosh Simonian; Naeim Ehtesham; Mohammad Reza Karimzadeh; Nasim Vatandoost; Babak Negahdari; Rasoul Salehi
Journal:  Cancer Gene Ther       Date:  2020-05-18       Impact factor: 5.987

6.  Homing of endogenous bone marrow mesenchymal stem cells to rat infarcted myocardium via ultrasound-mediated recombinant SDF-1α adenovirus in microbubbles.

Authors:  Gaofeng Su; Liyun Liu; Lingjie Yang; Yuming Mu; Lina Guan
Journal:  Oncotarget       Date:  2017-12-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.